Starting Dose of Latuda (Lurasidone)
For schizophrenia in adults and adolescents (13-17 years), start Latuda at 40 mg once daily with food (at least 350 calories); no initial titration is required. 1
Dosing by Indication
Schizophrenia
Adults:
- Starting dose: 40 mg once daily 1
- No initial titration needed
- Effective dose range: 40-160 mg/day
- Maximum dose: 160 mg/day
Adolescents (13-17 years):
- Starting dose: 40 mg once daily 1
- No initial titration needed
- Effective dose range: 40-80 mg/day
- Maximum dose: 80 mg/day
Bipolar Depression
Adults:
- Starting dose: 20 mg once daily (monotherapy or adjunctive with lithium/valproate) 1
- Effective dose range: 20-120 mg/day
- Maximum dose: 120 mg/day
Pediatric patients (10-17 years):
- Starting dose: 20 mg once daily (monotherapy) 1
- May increase after 1 week based on clinical response
- Effective dose range: 20-80 mg/day
- Maximum dose: 80 mg/day
Critical Administration Requirement
Latuda MUST be taken with food (at least 350 calories). 1 This is non-negotiable—administration with food increases absorption approximately 2-fold (AUC) and 3-fold (Cmax). Without food, patients receive subtherapeutic drug levels, which is a common pitfall leading to apparent treatment failure.
Dose Modifications for Special Populations
Renal Impairment
For moderate (CrCl 30-<50 mL/min) or severe (CrCl <30 mL/min) renal impairment: 1
- Starting dose: 20 mg/day
- Maximum dose: 80 mg/day
Hepatic Impairment
For moderate (Child-Pugh 7-9) or severe (Child-Pugh 10-15) hepatic impairment: 1
- Starting dose: 20 mg/day
- Moderate impairment maximum: 80 mg/day
- Severe impairment maximum: 40 mg/day
Clinical Considerations for Dose Selection
When to Consider Higher Starting Dose (80 mg)
Recent evidence suggests that in acute schizophrenia, starting at 80 mg/day may produce earlier reduction in positive symptoms compared to 40 mg/day, without increased discontinuation rates 2. Consider 80 mg starting dose when:
- Rapid control of positive symptoms or agitation is urgently needed
- Patient has no history of akathisia or movement disorder sensitivity
- Patient tolerates the dose well
However, this approach requires careful monitoring and is not FDA-approved as the standard starting dose. The FDA label remains clear that 40 mg is the recommended starting dose for schizophrenia 1.
Early Non-Response Strategy
If inadequate response (<20% PANSS improvement) at week 2: Consider dose escalation rather than immediate switching 3. The evidence supports re-evaluating at 2 weeks and potentially increasing from 80 mg to 160 mg in early non-responders, though this should be balanced against tolerability.
Dose-Response Relationship
The evidence shows a dose-related increase in efficacy and certain adverse events 4, 5, 6:
- 40 mg/day: Established efficacy with lowest akathisia risk (NNH=13)
- 80 mg/day: Optimal balance of efficacy and tolerability (NNH for akathisia=9)
- 120-160 mg/day: Higher efficacy for some outcomes but increased akathisia (NNH=6 at 120 mg) and somnolence without proportional benefit in many patients
Common Pitfalls to Avoid
- Forgetting food requirement: Always emphasize the 350-calorie meal requirement; this is the most common cause of apparent treatment failure
- Over-titrating too quickly: No initial titration is needed—start at therapeutic dose
- Exceeding maximum doses: Adolescents max at 80 mg/day (not 160 mg like adults)
- Ignoring renal/hepatic function: Always check and adjust starting dose accordingly
- Drug interactions: Lurasidone is metabolized via CYP3A4—avoid strong inhibitors (ketoconazole) and inducers (rifampin)
Alignment with Guidelines
The 2025 INTEGRATE guidelines emphasize using therapeutic doses from the start and assessing response at 4 weeks 7. The 2020 APA guidelines recommend antipsychotic treatment with monitoring for effectiveness and side effects 8. Both support the FDA-approved starting doses, with shared decision-making based on side-effect profiles and early assessment of treatment response.